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Introduction: This two-part phase 2 study evaluated the efficacy and 
safety of panitumumab, a fully human anti–epidermal growth factor 
receptor monoclonal antibody, combined with carboplatin/paclitaxel in 
patients with previously untreated advanced non–small-cell lung cancer.
Methods: In part 1, patients were sequentially enrolled to receive pacli-
taxel 200 mg/m2 and carboplatin (area under the concentration-ver-
sus-time curve, 6 mg/min/ml) plus panitumumab (1.0, 2.0, or 2.5 mg/
kg). In part 2, patients were randomized 2:1 to receive paclitaxel/ 
carboplatin with (arm A) or without (arm B) the maximum tolerated 
dose of panitumumab identified in part 1. Primary endpoints in parts 
1 and 2 were the incidence of dose-limiting toxicities and time to 
progression (TTP), respectively.
Results: In part 1, four of 19 patients had dose-limiting toxicities: 
three at 2.0 mg/kg (fatigue, pain in extremity, dyspepsia) and one 
at 2.5 mg/kg (rash). The maximum tolerated dose was not reached; 
panitumumab 2.5 mg/kg was selected for part 2. In part 2, TTP was 
18.1 weeks (95% confidence interval [CI], 13.6−23.3) in arm A and 
23.0 weeks (95% CI, 15.9−24.1) in arm B (hazard ratio, 0.9; 90% CI, 
0.66−1.21; p = 0.555). Progression-free survival in arms A and B was 
17.6 weeks and 18.3 weeks, respectively, and the objective response 
rate was 15.2% and 11.1%. Adverse events occurring more frequently 
in arm A than in arm B included skin toxicity, diarrhea, stomatitis, 
vomiting, and dizziness. Exploratory analyses did not demonstrate 
associations between potential biomarkers and outcomes.
Conclusion: Although toxicity was predictable and manageable, the 
addition of panitumumab to paclitaxel/carboplatin did not improve 
TTP in patients with previously untreated advanced non–small-cell 
lung cancer.
Key Words: Panitumumab, Paclitaxel/carboplatin, Non–small-cell 
lung cancer, KRAS, Epidermal growth factor receptor.
(J Thorac Oncol. 2013;8: 1510–1518)
Studies investigating the efficacy of epidermal growth fac-tor in the first-line treatment of advanced non–small-cell 
lung cancer (NSCLC) have yielded inconsistent results. In 
the phase 3 First-Line ErbituX in lung cancer (FLEX) study 
of patients with epidermal growth factor receptor (EGFR)–
expressing advanced NSCLC, overall survival (OS) was sig-
nificantly improved by first-line treatment with cetuximab 
plus cisplatin/vinorelbine versus cisplatin/vinorelbine alone.1 
In other studies, addition of cetuximab or the small-molecule 
EGFR inhibitors erlotinib and gefitinib to first-line chemo-
therapy did not improve outcomes.2–6
Some evidence has suggested that biomarkers could 
be used to identify NSCLC patients most likely to respond 
to EGFR inhibition.7 For example, among patients with 
chemotherapy-refractory NSCLC, only those with somatic 
EGFR mutations had longer progression-free survival (PFS) 
after treatment with gefitinib compared with treatment with 
docetaxel.8 Other potential biomarkers evaluated with anti-
EGFR monoclonal antibodies have included high EGFR gene 
copy number9 and tumor EGFR expression.10 Elevated EGFR 
protein expression and gene copy number have also been asso-
ciated with improved outcomes in studies with small- molecule 
EGFR inhibitors.11–15
Panitumumab is a fully human monoclonal antibody 
against EGFR, which has been shown to have activity as a 
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single agent and in combination with chemotherapy for the 
treatment of metastatic colorectal cancer, but it is not recom-
mended for use in patients whose tumors have mutations in 
codons 12 or 13 of KRAS.16,17 The aim of this two-part study 
was to evaluate the efficacy and safety of carboplatin/ paclitaxel 
with or without panitumumab in previously untreated patients 
with advanced NSCLC. The objective of part 1 was to estab-
lish either the maximum tolerated dose (MTD) or an appro-
priate dose of panitumumab plus carboplatin/paclitaxel for 
investigation in part 2. The primary objective of part 2 was to 
compare the time to progression (TTP) in patients receiving 
panitumumab plus carboplatin/paclitaxel or carboplatin/pacli-
taxel alone. In exploratory analyses, we assessed the ability of 
biomarkers to predict outcomes.
PATIENTS AND METHODS
Patients
Patients were eligible if they were aged at least 18 years, 
had pathologically confirmed NSCLC (stage IIIB with peri-
cardial or pleural effusion or stage IV) with 10% or more cells 
expressing EGFR, bidimensionally measurable disease, an 
Eastern Cooperative Oncology Group performance status of 1 
or less, life expectancy of 12 weeks or more, and an available 
paraffin-embedded tumor tissue sample. Exclusion criteria 
included prior therapy for NSCLC except radiation, surgery, 
or steroids; radiation therapy within 2 weeks of treatment ini-
tiation; investigational therapy within 30 days; other malig-
nancies within 5 years (except basal cell carcinoma, cervical 
carcinoma in situ, and primary NSCLC); hypercalcemia; and 
insufficient cardiac, hepatic, renal, or hematologic function. 
Brain metastases, if present, were to be controlled and asymp-
tomatic and not requiring treatment for at least 1 week.
The study protocol was approved by each center’s insti-
tutional review board. All patients provided signed informed 
consent before screening.
Study Design and Treatment
This was an open-label multicenter study conducted 
in two parts. Part 1 was a dose-escalation study of panitu-
mumab plus carboplatin/paclitaxel for untreated advanced 
NSCLC. Part 2 was a randomized study evaluating panitu-
mumab (at the dose determined in part 1) plus carboplatin/
paclitaxel versus carboplatin/paclitaxel alone in patients with 
advanced NSCLC.
Part 1
The primary endpoint of part 1 was the incidence of 
dose-limiting toxicities (DLTs). All patients received intra-
venous paclitaxel 200 mg/m2 (3.0-h infusion) and carboplatin 
6 mg/min/ml (0.5-h infusion) in 3-week cycles beginning on 
day 1 for up to six cycles. Patients were sequentially enrolled 
into three dose cohorts of five to 10 patients in which they 
received once-weekly 1-hour intravenous infusions of pani-
tumumab at doses of 1.0 mg/kg (cohort 1), 2.0 mg/kg (cohort 
2), or 2.5 mg/kg (cohort 3) for six cycles. The 2.5-mg/kg dose 
was anticipated to achieve circulating panitumumab concen-
trations exceeding those that result in 90% inhibition of tumor 
cell proliferation in xenograft models and cause less than 95% 
of patients to have skin rash. Patients without disease progres-
sion could receive panitumumab for an additional 18 weeks. 
Dose escalation into the next cohort began when the 3-week 
safety assessment was complete, five or more patients in the 
preceding cohort had been evaluated for DLT, and the MTD 
had not been reached. A DLT was defined as any treatment-
related adverse event (AE) requiring permanent discontinu-
ation of panitumumab, any treatment-related grade 3 or 4 
AE (except skin toxicity), or any treatment-related severe or 
life-threatening events not assessed by the National Cancer 
Institute Common Toxicity Criteria for Adverse Events ver-
sion 2.0. The MTD was defined as the dose level immediately 
below the dose that resulted in three of five (or 4 of 10) patients 
experiencing DLT attributed to panitumumab administration.
Part 2
In part 2, patients were randomized 2:1 to receive 
 carboplatin/paclitaxel at the same dose schedule as in part 1 
for up to six cycles with (arm A) or without (arm B) once-
weekly intravenous panitumumab at the dose identified in 
part 1. In the absence of progressive disease, patients could 
continue to receive panitumumab until disease progression or 
an AE that prevented further treatment occurred. The primary 
endpoint of part 2 was TTP. Secondary efficacy endpoints 
were OS time, PFS time, rate of progressive disease after 12 
weeks of treatment, overall response rate, and response rate 
after 6 weeks of treatment. Secondary safety endpoints were 
the incidence of AEs and changes in laboratory values and 
other safety parameters.
Tumor Response
Computed tomography or magnetic resonance imaging 
scans were performed every 6 weeks during the first 48 weeks 
of treatment and every 12 weeks thereafter. Tumor response 
was assessed using Response Evaluation Criteria in Solid 
Tumors.18 Objective responses (complete or partial) were con-
firmed 4 weeks or more (part 1) or 6 weeks or more (part 2) 
after criteria for response were first met. Response assess-
ments in part 2 were performed by blinded independent cen-
tral review (Bio-Imaging Technologies, Inc., Newtown, PA).
Safety
Safety was evaluated as the incidence of AEs (graded 
using National Cancer Institute Common Toxicity Criteria 
for Adverse Events version 2.0) and changes in laboratory 
tests. AEs were recorded from the start of treatment through 
the safety follow-up visit (which occurred within 4 weeks 
of the last administration of study medication). Fatal AEs 
were reported for at least 30 days after the last dose of study 
medication.
Assessment of Biomarkers
EGFR expression at screening was measured by immuno-
histochemistry of formalin-fixed, paraffin-embedded samples 
at a central laboratory (Impath Inc., New York, NY). Results 
were expressed as the percentage of cells stained at staining 
intensity scores ranging from 0 to 3+. Mutations in EGFR, 
KRAS (exons 2, 3, and 4), HRAS, NRAS, PIK3CA, and BRAF 
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were assayed by direct polymerase chain reaction sequenc-
ing of polymerase chain reaction–amplified genomic DNA 
extracted from FFPE samples. The proportion of patients with 
EGFR membrane staining, membrane and cytoplasmic stain-
ing, and cytoplasmic staining was assessed microscopically 
using previously published criteria.19
Statistical Analysis
The original planned sample size was 225 patients, 
which provided 85% power at the 10% significance level to 
detect a 50% improvement in TTP. However, enrollment was 
closed early at 175 patients after the publication of results dem-
onstrating a lack of survival benefit with erlotinib in combi-
nation with carboplatin/paclitaxel compared with  carboplatin/
paclitaxel alone.5
The analyses of efficacy and safety included all patients 
who received one or more doses of panitumumab, paclitaxel, 
or carboplatin until the data cutoff date (November 30, 2004). 
TTP was defined as the time from treatment initiation to dis-
ease progression or death due to disease progression. PFS was 
defined as the time from treatment initiation to disease pro-
gression or death. Time to event endpoints were summarized 
by the Kaplan-Meier method with two-sided 95% confidence 
intervals (CIs). Differences between treatment groups were 
assessed using a log-rank test at a two-sided 10% signifi-
cance level. Difference in TTP between the two arms was also 
assessed using a Cox proportional hazards model. Best over-
all response rate and the response rate after 6 weeks of treat-
ment were calculated with two-sided 95% CIs. The Fisher’s 
exact test was used to compare response rates between 
treatment groups.
RESULTS
Patients
Between January 7, 2002, and March 31, 2003, 194 
patients with advanced NSCLC were enrolled in the study. In 
part 1, 19 patients were enrolled at six study sites. In part 2, 
175 patients were enrolled at 50 study sites. Demographic and 
baseline characteristics were generally balanced (Table 1). 
Most patients had stage IV disease.
Treatment Exposure
All 19 patients in part 1 received one or more doses of 
panitumumab (cohort 1, n = 6; cohort 2, n = 7; cohort 3, n = 6). 
Patients in part 1 received a median of 21 (range, 6–38) pani-
tumumab infusions and a median of six (range, 4–6) cycles of 
chemotherapy. The median cumulative doses of paclitaxel in 
cohorts 1, 2, and 3 were 1027, 1012, and 975 mg/m2, respec-
tively. The median cumulative doses of carboplatin were 2339, 
1944, and 1467 mg/m2.
Of 175 patients randomized in part 2, 166 received 
study treatment (panitumumab plus carboplatin/paclitaxel 
[arm A], n = 112; carboplatin/paclitaxel alone [arm B], n = 
54). At the time of the data cutoff, four patients in arm A and 
five patients in arm B continued to receive treatment. Three 
patients in arm A completed 48 weeks of treatment. Reasons 
for discontinuation are listed in Figure 1. The median number 
of panitumumab infusions administered was 11 (range, 1–21). 
The median number of chemotherapy cycles was four in 
both treatment arms (interquartile range, arm A, 2–6; arm B, 
3–6). The median dose of paclitaxel was 197 mg/m2 per infu-
sion (range, 147–217) for arm A and 197 mg/m2 per infusion 
(range, 100–225) for arm B; the median dose of carboplatin 
was 372 mg/m2 per infusion (range, 234–688) and 364 mg/m2 
per infusion (range, 202–522) for arms A and B, respectively. 
The median cumulative paclitaxel dose was 788 mg/m2 (range, 
195–1241) in arm A and 904 mg/m2 (range, 100–1210) in arm 
B. The median cumulative carboplatin dose was 1314 mg/m2  
(range, 247–3057) in arm A and 1546 mg/m2 (range, 
268–2717) in arm B.
Dose Escalation (Part 1)
After 3 weeks of treatment, no patients in cohort 1 
had a DLT and one patient in cohort 2 had a DLT (fatigue). 
Consequently, dose escalation of panitumumab proceeded to 
the maximum dose of 2.5 mg/kg. Over the entire treatment 
period, four patients experienced DLTs: three in cohort 2 
(fatigue, pain in extremity, dyspepsia), and one in cohort 3 
(rash). The MTD was not reached, and panitumumab 2.5 mg/kg 
once weekly was the dose chosen for part 2.
Efficacy (Part 2)
At the time of data cutoff, a total of 137 disease pro-
gression events had occurred among patients who received 
treatment in part 2. There was no significant difference in TTP 
between the two treatment arms (log-rank test, p = 0.553; haz-
ard ratio, 0.9; 90% CI, 0.66–1.21; p = 0.555). The median TTP 
was 18.1 weeks (95% CI, 13.6–23.3) in arm A and 23.0 weeks 
(95% CI, 15.9–24.1) in arm B (Fig. 2).
Median PFS was 17.6 weeks (95% CI, 11.7–22.4) in 
arm A and 18.3 weeks (95% CI, 13.4–23.7) in arm B (log-rank 
test, p = 0.583; Fig. 3A). Median OS was 37.0 weeks (95% 
CI, 30.9–52.1) in arm A and 35.0 weeks (29.3–51.4) in arm B 
(p = 0.786; Fig. 3B).
The best overall response rate in arm A was 15.2% 
(95% CI, 9.1–23.2) and 11.1% (95% CI, 4.2–22.6) in arm B 
(Fisher’s exact test, p = 0.633; Table 2). All responses in part 2 
were partial responses. The best response rate after six cycles 
of treatment was 8.9% (95% CI, 4.4–15.8) in arm A and 9.3% 
(95% CI, 3.1–20.3) in arm B (p = 1.0). For the patients who 
responded, the median time to response was 5.6 weeks (range, 
5.0–29.4) in arm A and 5.4 weeks (range, 5.0–6.1) in arm B, 
and the median duration of response in the two arms was 24.1 
weeks (95% CI, 16.0–46.3) and 22.0 weeks (95% CI, 17.4–
32.1), respectively.
Safety (Part 2)
All patients who received treatment in part 2 experi-
enced at least one AE (Table 3). Ninety-four patients (84%) 
in arm A and 41 patients (76%) in arm B had a grade 3 or 
higher AE. AEs occurring more frequently in arm A than in 
arm B included skin toxicities, diarrhea, stomatitis, vomiting, 
and dizziness.
As expected, skin toxicities occurred more frequently 
in arm A versus arm B (88% versus 26%, respectively), 
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TABLE 1.  Patient Demographics and Baseline Characteristics
Part 1 Part 2
Panitumumab Plus  
Carboplatin/Paclitaxel (n = 19)
Arm A–Panitumumab Plus  
Carboplatin/Paclitaxel (n = 112)
Arm B–Carboplatin/Paclitaxel 
Alone (n = 54)
Age
  Median 50.0 61.5 62.0
  Range 36–82 36–83 42–81
Sex, n (%)
  Men 5 (26) 67 (60) 27 (50)
  Women 14 (74) 45 (40) 27 (50)
Race/ethnicity, n (%)
  White 19 (100) 101 (90) 46 (85)
  Black 0 (0) 7 (6) 7 (13)
  Asian 0 (0) 3 (3) 0 (0)
  Hispanic 0 (0) 1 (1) 1 (2)
  Other 0 (0) 0 (0) 0 (0)
ECOG performance score, n (%)
  0 6 (32) 37 (33) 15 (28)
  1 12 (63) 74 (66) 38 (70)
  2 1 (5) 1 (1) 1 (2)
Smoking statusa, n (%)
  Never — 10 (9) 6 (11)
  Former — 71 (63) 38 (70)
  Current — 28 (25) 9 (17)
Disease stage at diagnosis, n (%)
  I 2 (11) 13 (12) 4 (7)
  II 0 (0) 1 (1) 0 (0)
  IIIA 0 (0) 4 (4) 0 (0)
  IIIB 2 (11) 10 (9) 9 (17)
  IV 15 (79) 84 (75) 41 (76)
Disease histology at diagnosis, n (%)
  Adenocarcinoma 13 (68) 67 (60) 36 (67)
  Squamous cell carcinoma 3 (16) 23 (21) 12 (22)
  Other 3 (16) 22 (20) 6 (11)
Extent of disease at study entry, n (%)
  Distant metastasis 15 (79) 98 (88) 43 (80)
  Pleural effusion 8 (42) 31 (28) 19 (35)
  Pericardial effusion 4 (21) 11 (10) 0 (0)
Months since primary disease diagnosisb
  Median 2.0 1.5 1.1
  Range 0.7–21.3 0.2–119.2 0.2–27.6
Prior radiotherapy, n (%) 9 (47) 36 (32) 15 (28)
Percentage of cells with positive EGFR staining
  Median 100 100 100
  Range 20–100 10–100 26–100
Maximum EGFR staining intensity, n (%)
  1+ (weak) 0 (0) 8 (7) 0 (0)
  2+ (moderate) 3 (16) 11 (10) 5 (9)
  3+ (strong) 16 (84) 93 (83) 49 (91)
aSmoking history was not available for patients in part 1.
bTime from date of primary diagnosis or metastatic disease diagnosis to date of enrollment (part 1) or randomization (part 2).
ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor.
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with grade 3 toxicities occurring in 17% and 2% of patients, 
respectively. Diarrhea was reported in 48% and 26% of 
patients in arms A and B, respectively, with grade 3 diar-
rhea occurring in 6% and 2% of patients, respectively. 
Stomatitis of any grade was reported in 33% and 9% of 
patients in arms A and B, respectively, whereas the inci-
dence of hypomagnesemia across the two arms was similar 
(5% versus 4%, respectively; grade 3, 1% versus 0%). Of 
112 patients who received panitumumab plus carboplatin/
paclitaxel, 31 had possible panitumumab infusion reactions. 
Most were mild or moderate in severity; all but two patients 
who experienced infusion reactions received subsequent 
panitumumab infusions.
Seventeen deaths occurred during the study: one in part 
1 and 14 and two in arms A and B, respectively, in part 2. Most 
were attributable to disease progression. However, grade 5 AEs 
considered possibly related to panitumumab occurred in four 
patients in arm A in part 2 (respiratory failure secondary to 
progressive pulmonary fibrosis; gastrointestinal perforation; 
cerebrovascular accident, sepsis; and myocardial infarction).
In part 2, 27 patients (24%) in arm A discontinued the 
study (either the treatment or safety follow-up) owing to AEs. 
These included NSCLC (4%), rash (3%), and fatigue (2%). 
In arm B, nine patients (17%) discontinued the study owing 
to AEs. The only AE leading to discontinuation in more than 
one patient was neuropathy (4%). The percentage of patients 
discontinuing the study during the chemotherapy combination 
phase was similar in arms A (18%) and B (17%).
Associations between Biomarkers 
and Outcomes
Ninety-three patients had evaluable tumor samples for 
exploratory biomarker analysis. Among the 21 patients with 
somatic EGFR mutations who received treatment during the 
study, 12 received panitumumab plus carboplatin/paclitaxel, 
with three having a partial response (Table 4). Among the nine 
Assessed for eligibility in Part 2 (N=312)
Excluded (n=137)
Arm A Arm B
Received carboplatin/paclitaxel (n=54)
Did not receive carboplatin/paclitaxel (n=5)
Received panitumumab 2.5 mg/kg carboplatin/paclitaxel (n=112)
Did not receive panitumumab 2.5 mg/kg carboplatin/paclitaxel (n=6)
Ongoing (n=4) Ongoing (n=2)
Randomized (n=116) Randomized (n=59)
Completed 48 weeks of treatment (n=3)
Discontinued (n=1095)
Disease progression (n=68)
Investigator decision (n=7)
Adverse event (n=13)
Consent withdrawn (n=6)
Death (n=7)
Other (n=4)
Completed 48 weeks of treatment (n=0)
Discontinued (n=54)
Disease progression (n=28)
Investigator decision (n=11)
Adverse event (n=4)
Consent withdrawn (n=5)
Death (n=2)
Other (n=2)
Patient treated analysis set (n=112) Patient treated analysis set (n=54)
FIGURE 1.  CONSORT diagram for part 2.
 Events n (%) Median (95% CI)
Panitumumab + C/P 91 112 (81) 18.1 (13.6–23.3)
C/P alone 46 54 (85) 23.0 (15.9–24.1)
Patients at risk:
Panitumumab + C/P
C/P alone
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1515Copyright © 2013 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 8, Number 12, December 2013 Panitumumab Plus Carboplatin/Paclitaxel in NSCLC
patients who received carboplatin/paclitaxel alone, two had a 
partial response. Seventeen patients had somatic KRAS muta-
tions in exon 2. Among the 13 patients with KRAS mutations 
who received panitumumab plus carboplatin/paclitaxel, three 
had partial responses. Of the four patients who received carbo-
platin/paclitaxel, one had a partial response (Table 4). Because 
preclinical studies have suggested that KRAS mutations may 
influence cellular distribution of EGFR,19 we evaluated asso-
ciations between KRAS status and EGFR staining pattern. The 
proportion of patients with EGFR membrane staining, mem-
brane and cytoplasmic staining, and cytoplasmic staining was 
39%, 44%, and 17%, respectively, in patients with wild-type 
KRAS and 43%, 43%, and 13% in patients with mutant KRAS. 
Exploratory evaluations of tumor EGFR staining intensity and 
mutational status for other genes (PIK3CA, BRAF, HRAS, and 
NRAS) did not reveal conclusive associations with efficacy 
outcomes (data not shown).
DISCUSSION
In this study, panitumumab administered at 2.5 mg/kg 
once weekly in combination with carboplatin/paclitaxel did 
not improve median TTP (the primary endpoint) compared 
with carboplatin/paclitaxel alone. Similarly, median PFS 
and OS and overall response rate were not improved by the 
 Events n (%) Median (95% CI)
Panitumumab + C/P 97 112 (87) 17.6 (11.7–22.4)
C/P alone 49 54 (91) 18.1 (13.4–23.7)
Patients at risk:
Panitumumab + C/P
C/P alone
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 Events n (%) Median (95% CI)
Panitumumab + C/P 70 112 (63) 37.0 (30.9–52.1)
C/P alone 32 54 (59) 35.0 (29.3–51.4)
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FIGURE 3.  Median (A) progression-
free survival and (B) median overall 
survival in part 2. CI, confidence 
interval; C/P, carboplatin/paclitaxel.
TABLE 2.  Best Objective Response for Parts 1 and 2
Part 1 Part 2
Panitumumab  
1.0 mg/kg Plus 
Carboplatin/Paclitaxel 
(n = 6)
Panitumumab  
2.0 mg/kg Plus 
Carboplatin/Paclitaxel 
(n = 7)
Panitumumab  
2.5 mg/kg Plus 
Carboplatin/Paclitaxel 
(n = 6)
Arm A  
Panitumumab Plus 
Carboplatin/Paclitaxel 
(n = 112)
Arm B  
Carboplatin/Paclitaxel 
Alone (n = 54)
Complete response, n (%) 1 (17) 0 (0) 0 (0) 0 (0) 0 (0)
Partial response, n (%) 0 (0) 1 (14) 2 (33) 17 (15) 6 (11)
Stable disease, n (%) 5 (83) 5 (71) 3 (50) 63 (56) 36 (67)
Disease progression, n (%) 0 (0) 1 (14) 1 (17) 21 (19) 8 (15)
Not evaluable, n (%) 0 (0) 0 (0) 0 (0) 3 (3) 1 (2)
Overall response rate,a %  
(95% CI)
16.7 (0.4–64.1) 14.3 (0.4–57.9) 33.3 (4.3–77.7) 15.2 (9.1–23.2) 11.1 (4.2–22.6)
aAssessments made per Response Evaluation Criteria in Solid Tumors. Responses were confirmed at least 6 weeks after response criteria were first met.
CI, confidence interval.
1516 Copyright © 2013 by the International Association for the Study of Lung Cancer
Crawford et al. Journal of Thoracic Oncology ®  •  Volume 8, Number 12, December 2013
addition of panitumumab to carboplatin/paclitaxel. These 
results indicate that panitumumab does not provide clinical 
benefit in an unselected population of NSCLC patients.
Improvements in PFS and OS have been observed 
in studies investigating cetuximab as a first-line therapy in 
NSCLC. In the randomized phase 3 FLEX study (N = 1125), 
addition of cetuximab to cisplatin/vinorelbine resulted in a 
1.2-month improvement in OS (11.3 versus 10.1 months) and 
overall response rate (36% versus 29%).1 However, PFS was 
not improved (4.8 months in both arms). In the randomized 
phase 3 BMS099 study (N = 676), the addition of cetuximab 
to first-line taxane and platinum-based chemotherapy resulted 
in an improved overall response rate (26% versus 17%), but 
significant improvements in PFS (4.4 versus 4.2 months) and 
OS (9.7 versus 8.4 months) were not observed.6 Given that this 
study (N = 166) was not powered to detect a significant dif-
ference in OS between the treatment arms, the results are not 
inconsistent with those of FLEX and BMS099. Nonetheless, 
there were differences in the design of the studies that may 
have contributed to the differences in outcomes observed. 
Although this study and FLEX enrolled only patients with 
EGFR-expressing tumors as determined by immunohisto-
chemistry staining, FLEX required only one positively stained 
tumor cell, whereas this study required EGFR staining in 10% 
of tumor cells or more. There was no requirement for EGFR 
expression in BMS099. Patients with controlled brain metasta-
ses were accepted to this study and BMS099 but were ineligible 
for FLEX. Finally, there were differences in the chemotherapy 
regimens used in the three studies. The differences in OS (8.2, 
10.1, and 8.4 months, respectively) and ORR (11%, 29%, and 
17%, respectively) in the chemotherapy-alone arms of this 
study, FLEX, and BMS099, are consistent with the hypothesis 
that these differences in study design may have contributed 
to differences in outcomes. Overall, the results of this study, 
FLEX, and BMS099 suggest that any effects of anti-EGFR 
monoclonal antibodies are of limited magnitude in this setting.
Exploratory biomarker analyses did not identify associ-
ations between EGFR or KRAS mutational status and response 
to treatment with panitumumab in combination with carbopla-
tin/paclitaxel. Although it should be noted that the number of 
mutations identified in the biomarker analyses was small, the 
results are consistent with previous findings that KRAS muta-
tional status does not seem to be a strong predictor of outcome 
among patients who receive anti-EGFR therapy for NSCLC.20 
However, recent prospective biomarker analyses of phase 3 
studies have demonstrated that benefit from small-molecule 
EGFR inhibitors may be greater among patients with somatic 
EGFR mutations.8,15 In the Iressa NSCLC Trial Evaluating 
Response and Survival Versus Taxotere (INTEREST) study, 
in which gefitinib was noninferior to docetaxel, patients with 
somatic EGFR mutations who received gefitinib had longer 
PFS versus docetaxel (7.0 versus 4.1 months, respectively) 
whereas there was no difference in PFS among patients with 
wild-type EGFR (1.7 versus 2.6 months); similar results were 
observed for the objective response rate.8 In contrast, no asso-
ciation was observed between EGFR mutational status and 
TABLE 3.  Incidence of Adverse Events in Part 2a
Arm A–Panitumumab Plus Carboplatin/
Paclitaxel (n = 112)
Arm B–Carboplatin/Paclitaxel  
Alone (n = 54)
Any Grade Grade 3 or 4 Any Grade Grade 3 or 4
Patients, n (%) 112 (100) 94 (84) 54 (100) 41 (76)
  Fatigue 70 (63) 15 (13) 35 (65) 11 (20)
  Nausea 68 (61) 10 (9) 30 (56) 4 (7)
  Rash 66 (59) 13 (12) 9 (17) 0 (0)
  Diarrhea 54 (48) 7 (6) 14 (26) 1 (2)
  Constipation 51 (46) 6 (5) 21 (39) 2 (4)
  Alopecia 50 (45) 2 (2) 24 (44) 0 (0)
  Vomiting 49 (44) 9 (8) 17 (31) 5 (9)
  Arthralgia 39 (35) 6 (5) 22 (41) 3 (6)
  Dyspnea 38 (34) 12 (11) 15 (28) 4 (7)
  Anorexia 37 (33) 7 (6) 17 (31) 1 (2)
  Stomatitis 37 (33) 1 (1) 5 (9) 0 (0)
  Myalgia 36 (32) 3 (3) 14 (26) 2 (4)
Adverse events of interest, n (%)
  Skin toxicityb 98 (88) 19 (17) 14 (26) 1 (2)
  Dehydration 17 (15) 9 (8) 10 (19) 5 (9)
  Hypomagnesemia 6 (5) 2 (2) 2 (4) 0 (0)
  Pulmonary embolism 7 (6) 7 (6) 5 (9) 3 (6)
  Deep vein thrombosis 8 (7) 7 (6) 3 (6) 2 (4)
  Cardiac disorders 19 (17) 6 (5) 7 (13) 1 (2)
aIncidence of adverse events occurring in ≥30% of patients in either treatment arm in part 2, sorted by frequency in the panitumumab plus carboplatin/paclitaxel arm.
bIncludes all preferred terms for skin toxicity (including but not limited to rash and dermatitis acneiform).
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outcome with the addition of cetuximab to taxane- and plati-
num-based chemotherapy in BMS099,21 suggesting that there 
may be differences in the predictive value of EGFR muta-
tional status with small-molecule EGFR inhibitors compared 
with anti-EGFR monoclonal antibodies.
This study demonstrated that the combination of pani-
tumumab and carboplatin/paclitaxel had acceptable toxicity. 
The incidence and severity of certain commonly occurring 
toxicities observed in this study, including skin-related tox-
icities, gastrointestinal toxicities, and hypomagnesemia, 
were expected based on the results of studies that investi-
gated panitumumab monotherapy22–24 or in combination with 
chemotherapy25–29 in other solid tumors. The incidence and 
severity of these AEs was also consistent with those observed 
in phase 2 and 3 studies of cetuximab in combination with 
chemotherapy for the treatment of advanced NSCLC.1,30 A 
greater proportion of patients in arm A (24%) discontinued 
the study than in arm B (17%). This was likely because of a 
higher incidence of skin toxicity, particularly rash, in patients 
receiving panitumumab in combination with chemotherapy. 
The incidence of stomatitis among panitumumab-treated 
patients in this study was somewhat surprising. Stomatitis 
has been reported previously in studies of panitumumab 
monotherapy (18%) and cetuximab in combination with che-
motherapy (26%) in metastatic colorectal cancer22,31 although 
at lower frequencies.
TABLE 4.  Identification of Somatic Mutations in the EGFR and KRAS Genesa
Patient Sex Smoking Status Treatmentb EGFR Mutation KRAS Mutation Response
1 Male Former C/P Exon 18 (K713N)/Exon 19 (S752P) — SD
2 Female Former Panitumumab + C/P Exon 18 (L688P) Exon 2 (G12D) PR
3 Male Former Panitumumab + C/P Exon 18 (L688P) — PR
4 Male Former C/P Exon 18 (L688P) — PR
5 Male Current Panitumumab + C/P Exon 18 (L688P) — SD
6 Female Current C/P Exon 18 (L688P) — ND
7 Male Never C/P Exon 18 (L688P)/Exon 19 (∆AA 746–750) — PR
8 Female Former C/P Exon 18 (L688P)/Exon 21 (L828*) — SD
9 Female Never Panitumumab + C/P Exon 18 (Q701H) — PD
10 Male Current Panitumumab + C/P Exon 18 (Y727H) Exon 2 (G13D) SD
11 Female Never Panitumumab + C/P Exon 19 (∆AA 746–750) — PR
12 Female Current Panitumumab + C/P Exon 19 (D761N) — SD
13 Male Former C/P Exon 20 (N771InsH) Exon 2 (G12A) SD
14 Female Current C/P Exon 20 (N771InsH) — SD
15 Male Former C/P Exon 20 (N771InsH) — PR
16 Male Former Panitumumab + C/P Exon 20 (S768N) — PD
17 Male Former Panitumumab + C/P Exon 20 (T790M) — SD
18 Male Former Panitumumab + C/P Exon 21 (L828) — SD
19 Male Former Panitumumab + C/P Exon 21 (L858R) — SD
20 Male Never C/P Exon 21 (L858R) — SD
21 Male Former Panitumumab + C/P Exon 23 (3′ splice) — PD
22 Male Former Panitumumab + C/P — Exon 2 (G12C) PR
23 Male Former Panitumumab + C/P — Exon 2 (G12C) PR
24 Female Current C/P — Exon 2 (G12C) PR
25 Male Former Panitumumab + C/P — Exon 2 (G12C) PD
26 Female Former Panitumumab + C/P — Exon 2 (G12C) PD
27 Female Former Panitumumab + C/P — Exon 2 (G12C) PR
28 Male Former Panitumumab + C/P — Exon 2 (G12C) PD
29 Male Former Panitumumab + C/P — Exon 2 (G12D) PD
30 Male Former Panitumumab + C/P — Exon 2 (G12V) SD
31 Female Current Panitumumab + C/P — Exon 2 (G12V) SD
32 Female Former C/P — Exon 2 (G12V) SD
33 Female Current Panitumumab + C/P — Exon 2 (G13D) ND
34 Male Former Panitumumab + C/P — Exon 2 (G13D) PD
35 Male Former C/P — Exon 2 (Q22K) PD
aNinety-three samples sequenced.
bTwo patients who were enrolled but did not receive study treatment were found to have mutations in EGFR. The first had mutations in exon 19 (∆AA 746–750) and exon 21 
(R832H) and the second a mutation in exon 20 (N771InsH); neither patient had an objective response.
C/P, carboplatin/paclitaxel; ND, not done; PR, partial response; SD, stable disease; EGFR, epidermal growth factor receptor.
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Overall, panitumumab 2.5 mg/kg once weekly in com-
bination with carboplatin/paclitaxel seemed to have accept-
able toxicity in the first-line treatment of advanced NSCLC. 
However, there was no improvement in the primary efficacy 
endpoint of median TTP or the secondary efficacy endpoints 
(median PFS, OS, and response rate).
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